Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

BIO

For research use only.

Catalog No.S7198 Synonyms: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime

16 publications

BIO Chemical Structure

CAS No. 667463-62-9

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 97 In stock
USD 147 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's BIO has been cited by 16 publications

2 Customer Reviews

  • Lysates of HCT116p53KO cells were harvested 24 hs after treatment with different GSK3 inhibitors and GSK3A/B activation/inactivation checked by western blot: a mix of pSer21-GSK3A and pSer9-GSK3B antibodies and antibody cross-reacting with both pTyr279-GSK3A and pTyr216-GSK3B were used to assess the specificity of the inhibitor for GSK3A. BIO: 6-bromoindirubin-3'-oxime, TWS: TWS119, SB2: SB216763, SB4: SB415286.

    PLoS One 2014 9(7), e100947. BIO purchased from Selleck.

  • (e and f) Confocal immunofluorescence staining. U87 GSLCs and U251 GSLCs were seeded in suspension and treated with control, Tet, BIO or ICG-001 for 48 h. Blue fluorescence represents DAPI, red fluorescence represents β-catenin, and green fluorescence represents TUNEL. Scale bars, 40 μm

    Int J Oncol, 2017, 50(1):101-110. BIO purchased from Selleck.

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.
Features The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
Targets
GSK-3 [1]
(Cell-free assay)
TYK2 [4]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
5 nM 30 nM 0.08 μM 0.30 μM 0.32 μM
In vitro

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5. BIO interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos. [1] In human and mouse embryonic stem cells, BIO maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells. [2] BIO promotes proliferation in mammalian cardiomyocytes. [3]6BIO is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3. BIO selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEI-OC1 M4T0UGZ2dmO2aX;uJIF{e2G7 NYGwNJVuWHKxdHXjeIlwdiCjZ3HpcpN1KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gcoVwdmG2YXygcY92e2ViSFXJMW9EOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4F{eGG|ZT2zM|ch[WO2aY\peJktKEWFNUCgQUAxNjF7MjFOwG0v MkSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG5NVUoRjNyMEmxPVE2RC:jPh?=
SH-SY5Y M2H1dWZ2dmO2aX;uJIF{e2G7 NYS0WFVvUW6qaXLpeIlwdiCxZjDHV2s{NW2nZHnheIVlKGKndHGtZ4F{\WmwIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCVSD3TXVV[KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIF3HNVMzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvOjlizszNMi=> NVzCTZVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NVYyOTBpPkG4PFE3OTFyPD;hQi=>
K562 MnzHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MmXuO|IhcHK| NYG0emNVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlMh|ryPLh?= M1zRPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N|E1QTxxYU6=
IMR90 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3X3blczKGi{cx?= NIjIfXVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFnNVlkxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlkh|ryPLh?= MlvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEOxOFkoRjF7N{izNVQ6RC:jPh?=
HCT116 NV72cGE2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHmzco44OiCqcoO= MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iNT6yJO69VS5? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
HepG2 MoPzR5l1d3SxeHnjbZR6KGG|c3H5 NETuTI4zPCCqcoO= NEjzR2tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFI1KGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFUvOyEQvF2u MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2M{S5Nkc,Ojh5NEO0PVI9N2F-
HL60 NEnXPHBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NEfhZpY2KGSjeYO= MnLKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkSg{txONg>? Mor0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEOxOFkoRjF7N{izNVQ6RC:jPh?=
HuH7 M1L5bGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NH6xNmM4OiCqcoO= NYXRdpFHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC2MlIh|ryPLh?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
SH-SY5Y NEXiXYdEgXSxdH;4bYNqfHliYYPzZZk> NFfJWoM1QCCqcoO= M4XQb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDy[YR2[3Srb36gZZN{[XluIFnDOVAhRSB7IN88UU4> Ml7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MU[xNVAoRjF6OEG2NVExRC:jPh?=
SH-SY5Y MmrpSpVv[3Srb36gZZN{[Xl? M2X1eVQ5KGi{cx?= NUjodmd3W3W{dnn2ZYwhd2ZiaIXtZY4hW0hvU2m1XUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEmuOUDPxE1w NHHmbYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3QSd-MU[4OVQxPjl:L3G+
SH-SY5Y MWPGeY5kfGmxbjDhd5NigQ>? MYHE[YF1cCCxZjDoeY1idiCVSD3TXVV[KGOnbHzzJIlvKGGkc3XuZ4Uhd2ZiMkCgeW0hWS2YRD3PVIgh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEGwJO69VS5? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2PUc,OTZ6NUSwOlk9N2F-
SH-SY5Y MlHrSpVv[3Srb36gZZN{[Xl? NYLIXnFFTGWjdHigc4YhcHWvYX6gV2guW1l3WTDj[YxteyCrbjDwdoV{\W6lZTDv[kAzOCC3TTDRMXZFNU:SaDDifUBOXFNicnXkeYN1cW:wIHHzd4F6NCCLQ{WwJF0hOTNizszNMi=> MknDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y NIXNPVVHfW6ldHnvckBie3OjeR?= NHHiWFEzPCCqcoO= MoK2V5Vzfmm4YXygc4YhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSVIILl[JVkfGmxbjDhd5NigSxiSVO1NEA:KDF6IN88UU4> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2PUc,OTZ6NUSwOlk9N2F-
IMR32 MkDrR5l1d3SxeHnjbZR6KGG|c3H5 NH7KdGY1QCCqcoO= NWjvU4pRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUU2UM{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigQ>? NGXlXlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
SK-N-SH M1LJ[WN6fG:2b4jpZ4l1gSCjc4PhfS=> NELDfY01QCCqcoO= NWnMSoVCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7 NGrYUpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
NB39 MUTDfZRwfG:6aXPpeJkh[XO|YYm= MlPvOFghcHK| NV;KNpJOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkJ|OTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6 NXr1RVZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFI6PDdpPkKxPFAzQTR5PD;hQi=>
A673 NVWyXpNqeUiWUzDhd5NigQ>? MkHwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NW\tR25GeUiWUzDhd5NigQ>? NEnodWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NYD1c|ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MonKdWhVWyCjc4PhfS=> MljJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= M3vZdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NY\MT2NmeUiWUzDhd5NigQ>? NHjxOnByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NIHpcpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD M1X0[JFJXFNiYYPzZZk> Ml\odWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NHfjVlByUFSVIHHzd4F6 Mmf6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NWXuUHlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MUPxTHRUKGG|c3H5 NHnCbJZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MlPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NHHV[WFyUFSVIHHzd4F6 MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NIO1bIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M2ewXpFJXFNiYYPzZZk> MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MkXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MnXUdWhVWyCjc4PhfS=> NVn6UIdleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> M{jHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NInlWZFyUFSVIHHzd4F6 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 NVvL[G44eUiWUzDhd5NigQ>? NFX4VXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= M{DnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M1raO5FJXFNiYYPzZZk> MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC Mle5dWhVWyCjc4PhfS=> MlfQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NXHXT4d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NVPDVnh1eUiWUzDhd5NigQ>? M{P6bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz M1nLSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NXS5c4dDeUiWUzDhd5NigQ>? M2PmcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 Mn;PdWhVWyCjc4PhfS=> NWLoboJqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= M{XYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A549 MUXGeY5kfGmxbjDhd5NigQ>? NYjxTZh5OTBidV2= NHTYUVkyPSCvaX7z NVHnbm9EUW6qaXLpeIlwdiCxZjDoeY1idiCvUFfFV|Eh\nKxbTDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJHBITTJiYYSgNVAhfU1iYX\0[ZIhOTVibXnud{BjgSCKUFzD MkDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OUeyOFQoRjJ2Nkm3NlQ1RC:jPh?=
HEK293 Mln5SpVv[3Srb36gZZN{[Xl? MXqwMlUhfG9iMTD1US=> MXnJcohq[mm2aX;uJI9nKGi3bXHuJGdUUzNiYXP0bZZqfHliaX6gTGVMOjl|IHPlcIx{KGOxboThbY5qdmdidHjlJHdvfC:kZYThMYNifGWwaX6gZYN1cX[jdHXkJJJmeG:{dHXyJJBUfXCncmTPVGZNSVOKIDjTWGYzQTNiY3XscJMqKGG2IECuOUB1dyBzIIXNJIJ6KFewdDDy[ZBwenSncjDn[Y5mKGG|c3H5 M3vEOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nkm3NlQ1Lz5{NE[5O|I1PDxxYU6=
sf9 M3LKPWZ2dmO2aX;uJIF{e2G7 NHrGV|QyKHWP Mm\YTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? NUfqOodJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 NXHhWlh3TnWwY4Tpc44h[XO|YYm= NH7xb2syKHWP M3vifWlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhT1ONM3LleIEhME1zIITvJHQ1OjBicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BTSkWULVnSV5Rq\GViYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 NH;KdYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 MXvGeY5kfGmxbjDhd5NigQ>? MXixJJVO MoHKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMOiBqTUGgeI8hVDJ7ODDy[ZNq\HWnczmvR5lkdGmwIFGyJEhOOSC2bzDMOFMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegTIl{fG:wZTDINUBieyC|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk> NX3FO2hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MnzVSpVv[3Srb36gZZN{[Xl? MYGxJJVO NFjkb|dKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt3IDjNNUB1dyCSMkmyJJJme2mmdXXzLU9xOzWQQ1ugLG0yKHSxIGKzNFchemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzDSRk1EXEZiYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 NU\EbHpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MmHHSpVv[3Srb36gZZN{[Xl? M3HC[VEhfU1? NGfsc5RKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEG3cn;yZUBDKCiDMjD0c{BCOzR2IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegeIV1emFqTGLSUHNNTyliYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 M3HCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
sf9 MmjRSpVv[3Srb36gZZN{[Xl? MVuxJJVO NX32bmtRUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCIR1\SNUApTzRyMDD0c{BTQDJyIILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy|IHH0JFEhfU1idYPpcochWG:ueTjHcJUtXHm{KUS6NUBieyC|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 NHPYU3BHfW6ldHnvckBie3OjeR?= MmfDNUB2VQ>? MXLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEOGS{GgLG0yKHSxIF2yPVchemW|aXT1[ZMqN0O7Y3zpckBDOSBqTUGgeI8hXjR|MzDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHJDNUOWRjDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= MorSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 NFHqdYhHfW6ldHnvckBie3OjeR?= NFOwUI8yKHWP NYOyOFZ3UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNMjCoUVEhfG9iTEK5PEBz\XOrZIXld{kwS3mlbHnuJGUyKCiPMTD0c{BCOzl3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegVmIuS1SIIHHzJJN2[nO2cnH0[UBjgSCoaXz0[ZIh[mmwZHnu[{Bie3OjeR?= NEjyeoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 M4T2T2Z2dmO2aX;uJIF{e2G7 NE\sO|QyKHWP NE\QXW1KdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEG3cn;yZUBCKCiPMTD0c{BUPDB|IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy|IHH0JFEhfU1idYPpcochfGW2cnGoUHJTVFOORzmgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 NX7tNpU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 NY\VV4h{TnWwY4Tpc44h[XO|YYm= MmCyNUB2VQ>? NIL4eVZKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDBeZJwemFiQjCoUVEhfG9iU{K3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IHH0JFEhfU1idYPpcochS0SFMkXDMYRmemm4ZXSgdIVxfGmmZTDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
HT22 NUXVc5NMTnWwY4Tpc44h[XO|YYm= Mn3ONVAhfU1? NVrqRW9rOjRiaILz Ml;VTY5pcWKrdHnvckBw\iCJU1uzMY1m\GmjdHXkJIJmfGFiY3Hz[YlvKHCqb4PwbI9zgWyjdHnvckBqdiCvb4Xz[UBJXDJ{IHPlcIx{KGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhVUdzM{K= MmPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OUi0OFMoRjJ{OUm4OFQ{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p21 / p27 ; 

PubMed: 27510556     


In BIO treatment of cardiac fibroblasts for 1 day, the protein levels of phosphorylated Akt, p21, and p27 were assessed.

p-β-catenin / β-catenin ; 

PubMed: 27211495     


ERKi and GSK3i differently regulate PI3K/Akt and β-catenin pathways. U0126 increased while BIO decreased Akt phosphorylation after 24 hours of treatment. BIO prevented β-catenin phosphorylation leading to intact β-catenin accumulation, while U0126 only had a marginal effect.

FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 ; 

PubMed: 27211495     


U0126 markedly increased the phosphorylation of Akt downstream targets FOXO1 and FOXO3a, while BIO decreased it.

27510556 27211495
Immunofluorescence
pAKT / p21 / p27 ; 

PubMed: 27510556     


Protein expressions of pAkt, p21 and p27 were determined by immunofluorescence staining in cardiac fibroblasts treated with BIO for 1 day. *p < 0.05, t-test. Scale bar = 100 μm.

TNF-α; 

PubMed: 24286133     


Detection of TNF-α protein expression by immunofluorescence microscopy. Nucleus pulposus cells were cultured with or without 1.0 μM BIO for 24 h, fixed, and stained with an antibody against c-fos. Left: cells stained with an antibody to TNF-α; middle: cells stained with 4′,6-diamidino-2-phenylindole (DAPI), to identify healthy nuclei; right: cells stained with an antibody to TNF-α and with DAPI. Scale bar, 50 μm (original magnification, 20×).

E-cadherin / Nanog ; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty-four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Nanog.

Oct3/4; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty‐four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Oct3/4. In contrast, long-term BIO treatment leads to opposing results. Scale bar = 20 µm.

27510556 24286133 25538040
Growth inhibition assay
Cell proliferation ; 

PubMed: 27510556     


The increase in cardiomyocyte proliferation after treatment with BIO for 4 days was also confirmed by MTT assay.

27510556
In vivo BIO suppresses melanoma tumor growth in a mouse xenograft model. [4]

Protocol

Kinase Assay:[1]
- Collapse

Kinase assay:

Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-32P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.
Cell Research:[1]
- Collapse
  • Cell lines: COS1, Hepa or SH-SY5Y cells
  • Concentrations: ~10 μM
  • Incubation Time: 12 or 24 h
  • Method: COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ∼70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: mouse
  • Dosages: 50 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 71 mg/mL (199.34 mM)
Ethanol 6 mg/mL (16.84 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.
3 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 356.17
Formula

C16H10BrN3O2

CAS No. 667463-62-9
Storage powder
in solvent
Synonyms GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime
Smiles C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04263519 Not yet recruiting Drug: Tacrolimus Alzheimer Disease|Mild Cognitive Impairment Massachusetts General Hospital December 1 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

GSK-3 Signaling Pathway Map

Related GSK-3 Products

Tags: buy BIO | BIO supplier | purchase BIO | BIO cost | BIO manufacturer | order BIO | BIO distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID